No significant differences in the FGFR4 expression and survival rates were observed in all patients with lung adenocarcinoma and in lung adenocarcinoma patients with mutant-type EGFR. Therefore, the expression level of FGFR4 may provide clinical significance for the survival rate of lung adenocarcinoma patients with wild-type EGFR. Here, EGFR is linked to lung adenocarcinoma.